This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
← catalyst calendarNCT07028853 · readout in 754 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,000estimated
Sites
337
Countries
Argentina, Australia, Belgium +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-28 | actual | When the study began enrolling |
| Primary completion | 2028-09-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-12-08 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Hormone Sensitive Prostate Cancer
- Prostate Cancer
- Cancer of the Prostate
Interventions
- Drug: Mevrometostat — also filed as PF-06821497
- Drug: Placebo
- Drug: Enzalutamide — also filed as Xtandi
Primary outcome
what the primary-completion date above is the date OFRadiographic Progression Free Survival (rPFS)
measured Randomization up to approximately 4 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed